GENTILE, Massimo
 Distribuzione geografica
Continente #
EU - Europa 152
Totale 152
Nazione #
IT - Italia 152
Totale 152
Città #
Rome 75
Gioiosa Ionica 70
Lamezia Terme 4
Villa San Giovanni 3
Totale 152
Nome #
Myelodysplastic syndromes with ring sideroblasts, file e11ac152-dc2f-4ab3-9f8c-e73c528e7017 7
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period, file 84444741-7ecf-4514-8f97-4883d54eef1d 6
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis, file b31b3636-8fc4-4223-9207-eac602e8d69c 6
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis, file b5be8cfd-efe3-4491-b583-24f063014d80 5
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura, file d25f0151-63fb-4b7b-8fc1-1c2067496d31 5
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report, file f6ae86b7-a149-4589-aa27-c18c6d79654b 5
Acalabrutinib in chronic lymphocytic leukemia, file 0322a7aa-e716-413d-baf0-5cf55bd8f9f2 4
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination, file 148d0cf9-6457-49fe-8699-aa2341730077 4
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia, file 2dbc7cb5-e93e-4c87-ac6d-d70193703aae 4
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials, file 5e146688-8155-4947-b4c6-a2cc0f6836c3 4
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients, file 730e8026-212b-4a79-b648-e4d094ddcbcb 4
Isatuximab in multiple myeloma, file 776f4e0e-ad9e-49cd-879b-3664c83e2080 4
Cerebral pheohyphomycosis due to curvularia species, file 7902ff2f-8af3-41f6-9452-53b0448ec0f8 4
Venetoclax for the treatment of chronic lymphocytic leukemia., file 7a78e161-4f9a-4d82-83b2-f33c280b0861 4
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials, file 83e09d9e-4612-4446-88a1-01a710493976 4
Elotuzumab in multiple myeloma, file c9cddd10-aa59-47cd-b154-98c2c147afe2 4
Zanubrutinib for the treatment of chronic lymphocytic leukemia, file ccf8894b-d154-45cf-8afb-a7689383758e 4
Venetoclax in acute myeloid leukemia, file d91f253d-75a9-4140-9f32-5ca05acb5ed2 4
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol, file f5a03718-9a3d-420f-bd65-2034a9adc049 4
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement, file 48f0dde8-dd7a-4ce4-8dbb-f03c26bb5cc8 3
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma, file 045fb3ab-eccf-4b74-b260-ffa60a7ce21c 2
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients, file 0a320765-792f-4cc3-bb4d-5f8296fc3ca5 2
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report, file 12d2ebe9-57d1-4f6e-83f7-257b400617d9 2
Belantamab mafodotin in multiple myeloma, file 14a801e1-d596-414c-9ad4-8db522cd7b33 2
Iron chelation therapy, file 1dfc79b8-0148-4ab4-9482-c76cf64a3588 2
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials., file 2ba86413-8906-4f05-bdc7-e7a0c6e01ce4 2
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature, file 383ad9ad-4093-485b-9788-22188c63063a 2
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement, file 4636acb6-384e-4a2c-9dc4-7f164e57bbd1 2
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients, file 4e4b9640-74c0-475f-91bd-4e968803bbc0 2
Tagraxofusp in myeloid malignancies, file 4ee8472b-a624-44e5-91b9-dee2d93c3237 2
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing, file 5303487c-4d58-45cd-9ea4-77ee98e4bc30 2
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations, file 614f66ff-81bc-45d7-b4b6-ab98e705d0a0 2
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities, file 636ea4d0-1d16-4a0f-aae4-a622c6cec45e 2
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment, file 714c6627-de38-4e0d-bdf6-0f46806a8f05 2
Glasdegib for the treatment of acute myeloid leukemia, file 804aff4e-5107-4695-9503-fac90e431993 2
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma, file 81c052a3-3263-4024-bd4f-df3edaa1e73a 2
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials, file 85b4b71b-b9a2-4815-a6d4-f3b29133abc6 2
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study, file 88ca3e9f-3451-437d-9f45-1f6abf41ee46 2
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma., file 8b9fa2c8-c8ed-4725-b9e3-a8eac2356a1a 2
Panobinostat for the treatment of acute myelogenous leukemia., file 8bdc9d96-3a5c-4570-a67b-b40b215d9ce4 2
Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence., file 92c43a46-9444-4dc0-8cdb-34700f5a005d 2
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study, file abfaf3c2-c279-4cf4-84f0-01ebd97acdbd 2
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases, file b1811dac-0762-4cdd-93d2-5a90732f7562 2
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials, file b480e67a-d732-4a6e-b442-eb4c33a2857f 2
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort, file bd35d34d-0266-4613-9d87-6c6fda09ff53 2
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study, file ca8791bb-99cf-4c60-8607-782f311e8e4f 2
Ivosidenib in acute myeloid leukemia, file e577ed41-4975-4140-a18b-21dd973314da 2
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia, file e71b6fe0-c6a7-474d-b410-beda3ec2de59 2
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia, file e806c803-be51-401a-9258-acba8414b73b 2
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant, file f1b6bea3-4976-48d1-87df-039b9e0db4dc 2
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells, file 2f68e3fc-6145-4304-8eac-d73cd1c7830e 1
Teclistamab-cqyv in multiple myeloma, file 7749fa58-0fa5-43ff-b98e-fe0f98567225 1
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi., file d0eb58f4-d1fc-4f91-94e1-603add44cbab 1
Totale 152
Categoria #
all - tutte 156
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 156


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20237 0 0 0 0 0 0 3 0 4 0 0 0
2023/2024145 0 0 0 0 0 75 70 0 0 0 0 0
Totale 152